Publications by authors named "Mark J Huffmyer"
Article Synopsis
- The introduction discusses the concerns surrounding the use of disease-modifying therapies for Alzheimer's disease, such as their clinical benefits, risks, costs, and the hesitation of clinicians to prescribe them.
- The study compares lecanemab, an anti-amyloid therapy for Alzheimer's, with four other biologic agents used in various diseases, focusing on their costs, benefits, and risks.
- Results indicate that the costs, clinical benefits, and safety of anti-amyloid therapies are similar to those of the other biologics, suggesting a promising future for Alzheimer's treatments.
Purpose: Developing effective deprescribing interventions relies on understanding attitudes, beliefs, and communication challenges of those involved in the deprescribing decision-making process, including the patient, the primary care clinician, and the pharmacist. The objective of this study was to assess patients' beliefs and attitudes and identify facilitators of and barriers to deprescribing.
Methods: As part of a larger study, we recruited patients ⩾18 years of age taking ⩾3 chronic medications.
Background: Older adults are especially susceptible to adverse effects of inappropriate medication therapy, and anticholinergic medications are common culprits for cognitive dysfunction due to their action on the central nervous system. Medication therapy management (MTM) interventions can aid in deprescribing and reducing inappropriate medication use in older adults. However, there is sparse literature on the long-term sustainability of these interventions.
View Article and Find Full Text PDF